Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;12(7):963-966.
doi: 10.1002/alr.22946. Epub 2022 Jan 14.

Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del

Daniel M Beswick  1 , Stephen M Humphries  2 , Connor D Balkissoon  3 , Matthew Strand  4 , Jessa E Miller  1 , Aastha Khatiwada  4 , Eszter K Vladar  5   6 , David A Lynch  2 , Jennifer L Taylor-Cousar  5   7
Affiliations

Olfactory dysfunction in people with cystic fibrosis with at least one copy of F508del

Daniel M Beswick et al. Int Forum Allergy Rhinol. 2022 Jul.
No abstract available

Keywords: CFTR modulator therapy; computed tomography; cystic fibrosis; olfaction; olfactory cleft; quality of life; smell testing.

PubMed Disclaimer

Conflict of interest statement

Daniel M. Beswick: Medtronic, prior consultant (ended 2020); Stephen M. Humphries: Boehringer Ingelheim, Parexel and Imidex, consultant not affiliated with this work; David A. Lynch: Parexel, Boehringer Ingelheim, Siemens, Veracyte, consultant, not related to this work; Jennifer L. Taylor‐Cousar: received grants from Vertex Pharmaceuticals Incorporated, Gilead, N30, Celtaxsys, Proteostasis, and Bayer; has received fees from Vertex Pharmaceuticals Incorporated related to consultation on clinical research design, participation on advisory boards, and speaking engagements; has received speaking fees from Celtaxsys; and has served on advisory boards and/or provided consultation for Novartis, Genentech, Gilead, Protalix, Santhera, 4DMT, AbbVie, and Proteostasis; Connor D. Balkissoon, Matthew Strand, Jessa Miller, and Eszter K. Vlada: none.

References

    1. Di Lullo AM, Iacotucci P, Comegna M, et al. Cystic fibrosis: the sense of smell. Am J Rhinol Allergy. 2020;34:35–42. - PubMed
    1. Lindig J, Steger C, Beiersdorf N, et al. Smell in cystic fibrosis. Eur Arch Otorhinolaryngol. 2013;270:915–921. - PubMed
    1. Saltagi AK, Saltagi MZ, Nag AK, et al. Diagnosis of anosmia and hyposmia: a systematic review. Allergy Rhinol (Providence). 2021;12:21526567211026568. - PMC - PubMed
    1. Beswick DM, Humphries SM, Balkissoon CD, et al. Impact of CFTR therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient reported outcomes. Ann Am Thorac Soc. Published online August 26, 2021. 10.1513/annalsats.202101-057oc - DOI - PMC - PubMed
    1. Beswick DM, Humphries SM, Balkissoon CD, et al. Olfactory dysfunction in cystic fibrosis: impact of CFTR modulator therapy. J Cyst Fibros. Published online September 28, 2021. 10.1016/j.jcf.2021.09.014 - DOI - PubMed

Publication types

MeSH terms

Substances